iRhythm Posts First Quarterly Profit Amid Strong Revenue Growth
Event summary
- iRhythm reported $208.9 million in Q4 revenue, up 27.1% YoY, and its first quarterly GAAP net income of $5.6 million.
- Full-year 2025 revenue hit $747.1 million, a 26.2% increase from 2024, with gross margin expanding to 70.6%.
- Adjusted EBITDA for 2025 reached $68.9 million, a $76.7 million improvement YoY.
- The company ended 2025 with $583.8 million in unrestricted cash and marketable securities.
The big picture
iRhythm's transition to profitability marks a strategic milestone in the digital health sector, where scaling operational efficiencies and expanding margins are critical. The company's focus on proactive arrhythmia detection aligns with broader healthcare trends toward preventative care and data-driven diagnostics. Its ability to sustain this momentum will depend on executing its global expansion plans while navigating competitive pressures from established players like Baxter International.
What we're watching
- Revenue Growth Sustainability
- Whether iRhythm can maintain its fifth consecutive quarter of over 20% YoY revenue growth amid increasing competition.
- Operational Efficiency
- How the company will balance volume-related cost increases with margin expansion goals in 2026.
- Market Expansion
- The pace at which iRhythm can scale its platform globally while advancing its next-generation product roadmap.
Related topics